Skip to
China
Firm | Deal | Value | Client | Lawyer(s) involved |
Davis Polk & Wardwell | $35 billion | Uber |
| |
Cyril Amarchand Mangaldas | $1.3 billion | Gland Pharma | Cyril Shroff , Reeba Chacko, Bharat Budholia, S.R. Patnaik (Partners) | |
Fangda
| $35 billion | Didi Chuxing | Tan Peng (Partner) | |
Han Kun | $35 billion | Uber | Charles Li, Xu Ying, Ma Cheng, Chen Rong, Huang Wei (Partners) | |
Khaitan & Co | $1.3 billion | Fosun Pharmaceutical | Niren Patel (Partner) | |
Latham & Watkins | $2 billion | Vizio | Scott Shean, David Lee (Partners) | |
Simpson Thacher & Bartlett | $1.3 billion | Gland Pharma |
| |
Skadden Arps Slate Meagher & Flom | $35 billion | Didi Chuxing | Julie Gao, Will Cai, David Rievman, Nathan Giesselman, Steven Sunshine, Matthew Hendrickson, Rory McAlpine (Partners) | |
Skadden Arps Slate Meagher & Flom | Investor consortium's investment in Yixin Capital | $500 million | Bitauto and Yixin Capital | Julie Gao, Haiping Li (Partners) Hongtao Lu, Yuling Geng, William Zhu, Peter Pang (Associates) |
Skadden Arps Slate Meagher & Flom | Trina Solar’s going private transaction | $1.1 billion | Investor consortium | Peter Huang (Partner) James Chang, Ning Dong, Peter Qiu (Associates) Andrew Foster, Kexin Li (Counsel) |
Skadden Arps Slate Meagher & Flom | $2 billion | Le Holdings | Julie Gao, Michael Gisser, Michael Mies, Will Cai, Stuart Levi, Karen Corman, David Kitchen, Sean Shimamoto, Ivan Schlager, Ken Schwartz (Partners) | |
Troutman Sanders | $1.3 billion | Shanghai Fosun Pharmaceutical Group |
| |
Walkers | $35 billion | Uber | Amelia Hall, Denise Wong, Joanne Collett (Partners) William Lee (Associate) |
Hong Kong
Firm | Deal | Value | Client | Lawyer(s) involved |
Davis Polk & Wardwell | Greenland Hong Kong’s issue of 3.875% notes due 2019 | $450 million | Greenland Hong Kong Holdings | Paul Chow (Partner) Christine Xu (Associate) Xuelin (Steve) Wang (Registered Foreign Lawyer) |
Linklaters | Link REIT’s inaugural green bonds | $500 million | Underwriters | Jon Horan (Partner) Gloria Cheung (Counsel) |
Linklaters | Biostime’s concurrent high yield notes, syndicated facility and convertible bond tender offer | $400 million, 450 million | Lead manager | Mark Hageman, Davide Mencacci, Jon Horan (Partners) |
Back to top